Immunogenicity and Safety of High-Dose Quadrivalent Influenza Vaccine (SP0178) Administered by Intramuscular Route Versus Standard-Dose Quadrivalent Influenza Vaccine by Subcutaneous Route in Subjects 60 Years of Age and Older in Japan
Latest Information Update: 06 Oct 2023
At a glance
- Drugs Influenza virus vaccine (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors Sanofi Pasteur
- 09 Mar 2023 Results assessing the immunogenicity and safety of the split-virion inactivated quadrivalent influenza vaccine administered intramuscularly compared with a locally licensed standard-dose influenza vaccine administered subcutaneously in Japan, published in the Vaccine.
- 15 Jan 2021 Status changed from active, no longer recruiting to completed.
- 07 Dec 2020 Status changed from recruiting to active, no longer recruiting.